PIPELINE Press Archives - DMK Pharmaceuticals

Effect of DPI-125 on opioid withdrawal behaviors in rats: a comparison study with methadone and buprenorphine

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson’s disease.

The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability

Sign Up For DMK Pharmaceuticals Email Alerts

DMK Pharmaceuticals is a clinical stage neuro-biotechnology company focused on the development and commercialization of potential blockbuster products for the treatment of a variety of neuro-based disorders with significant unmet medical needs.

Category: PIPELINE Press

Effect of DPI-125 on opioid withdrawal behaviors in rats: a comparison study with methadone and buprenorphine

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson’s disease.

The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability

Sign Up For DMK Pharmaceuticals Email Alerts

COMPANY

PRODUCTS

PIPELINE

INVESTORS & MEDIA

CONNECT

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?